a national strategy for prevention and control of hepatitis B and C /
First Statement of Responsibility
Heather M. Colvin and Abigail E. Mitchell, editors ; Committee on the Prevention and Control of Viral Hepatitis Infections, Board on Population Health and Public Health Practice.
Introduction -- Surveillance -- Knowledge and awareness about chronic hepatitis B and hepatitis C -- Immunization -- Viral hepatitis services.
0
SUMMARY OR ABSTRACT
Text of Note
"The global epidemic of hepatitis B and C is a serious public health problem. Hepatitis B and C are the major causes of chronic liver disease and liver cancer in the world. In the next 10 years, 150,000 people in the United States will die from liver disease or liver cancer associated with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. Today, between 800,000 and 1.4 million people in the United States have chronic hepatitis B and between 2.7 and 3.9 million have chronic hepatitis C. People most at risk for hepatitis B and C often are the least likely to have access to medical services. Reducing the rates of illness and death associated with these diseases will require greater awareness and knowledge among health care workers, improved identification of at-risk people, and improved access to medical care. Hepatitis B is a vaccine-preventable disease. Although federal public health officials recommend that all newborns, children, and at-risk adults receive the vaccine, about 46,000 new acute cases of the HBV infection emerge each year, including 1,000 in infants who acquire the infection during birth from their HBV-positive mothers. Unfortunately, there is no vaccine for hepatitis C, which is transmitted by direct exposure to infectious blood. Hepatitis and Liver Cancer identifies missed opportunities related to the prevention and control of HBV and HCV infections. The book presents ways to reduce the numbers of new HBV and HCV infections and the morbidity and mortality related to chronic viral hepatitis. It identifies priorities for research, policy, and action geared toward federal, state, and local public health officials, stakeholder, and advocacy groups and professional organizations."--Publisher's description.
OTHER EDITION IN ANOTHER MEDIUM
Title
Hepatitis and liver cancer.
International Standard Book Number
9780309146289
TOPICAL NAME USED AS SUBJECT
Hepatitis B-- United States.
Hepatitis C-- United States.
Liver-- Cancer-- United States.
Hepatitis B-- complications.
Hepatitis B-- prevention & control.
Hepatitis C-- complications.
Hepatitis C-- prevention & control.
Liver Neoplasms-- prevention & control.
Viral Hepatitis Vaccines-- therapeutic use.
HEALTH & FITNESS-- Diseases-- Cancer.
Hepatitis B.
Hepatitis C.
Liver-- Cancer.
MEDICAL-- Oncology.
GEOGRAPHICAL NAME USED AS SUBJECT
United States.
United States.
2
7
(SUBJECT CATEGORY (Provisional
HEA-- 039030
M
MED-- 062000
DEWEY DECIMAL CLASSIFICATION
Number
616
.
99/436
Edition
22
LIBRARY OF CONGRESS CLASSIFICATION
Class number
RA644
.
H4
Book number
H37
2010eb
OTHER CLASS NUMBERS
Class number
2010
G-059
Class number
WC
536
Book Number
H5322
2010
PERSONAL NAME - ALTERNATIVE RESPONSIBILITY
Colvin, Heather M.
Mitchell, Abigail E.
CORPORATE BODY NAME - ALTERNATIVE RESPONSIBILITY
Institute of Medicine (U.S.)., Board on Population Health and Public Health Practice.
Institute of Medicine (U.S.)., Committee on the Prevention and Control of Viral Hepatitis Infections.